Cluster of Differentiation 3 (CD3) Antibody Market Report 2026

The cluster of differentiation 3 (cd3) antibody market size has grown rapidly in recent years. It will grow from $1.99 billion in 2025 to $2.27 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to advancements in monoclonal antibody therapeutics, increasing clinical research on t-cell biology, rising prevalence of cancer indications, expansion of hospital-based immunotherapy programs, growing role of contract research organizations.

The cluster of differentiation 3 (cd3) antibody market size is expected to see rapid growth in the next few years. It will grow to $3.74 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to growing pipeline of t-cell engaging therapies, increasing approvals of antibody-based immunotherapies, rising investments in oncology research, expansion of personalized immune treatments, increasing focus on reducing immune-related adverse events. Major trends in the forecast period include increasing development of t-cell redirecting therapies, rising adoption of bispecific cd3 antibodies, growing use of cd3 in cancer immunotherapy, expansion of fc-engineered antibody platforms, enhanced focus on immune modulation precision.

The rising prevalence of cancer is expected to drive growth in the cluster of differentiation 3 (CD3) antibody market going forward. Cancer prevalence refers to the total number of individuals, both newly and previously diagnosed, living with a history of cancer at a given time. The increasing prevalence is largely driven by lifestyle-related risk factors, including poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, which elevate the likelihood of developing various cancers. CD3 antibodies support cancer treatment by activating and directing T-cells to target malignant cells. They improve immune response efficiency, making them effective against both hematologic and solid tumors. For instance, in February 2025, according to Cancer Australia, an Australia-based government agency, there were 4,641 new pancreatic cancer cases in 2024, with 2,414 in males and 2,227 in females. Therefore, the rising cancer prevalence is propelling the growth of the CD3 antibody market.

Key companies in the CD3 antibody market are focusing on advanced therapies such as bispecific antibodies to enhance treatment efficacy, improve cancer-cell targeting, and reduce relapse in heavily pretreated patients. Bispecific antibodies are engineered biologic therapies that bind simultaneously to two different antigens, redirecting the patient’s immune cells to attack cancer cells. For example, in August 2023, Johnson & Johnson, a US-based pharmaceutical company, received FDA approval for Talvey (talquetamab-tgvs), a bispecific T-cell engaging antibody therapy for patients with relapsed or refractory multiple myeloma. The therapy binds CD3 on T-cells and GPRC5D on myeloma cells, offering precise T-cell redirection and off-the-shelf use without individualized CAR-T cell manufacturing. It improves treatment accessibility, immune-mediated tumor killing, and outcomes for heavily pretreated patients.

In December 2023, Danaher Corporation, a US-based biotechnology company, acquired Abcam plc for $5.7 billion. This acquisition strengthens Danaher’s position in the life sciences and proteomics market by expanding its portfolio of research reagents, antibodies, and related solutions for drug discovery and diagnostics. Abcam plc is a UK-based life sciences company providing CD3 antibodies for immunology and cancer research.

Major companies operating in the cluster of differentiation 3 (cd3) antibody market are Johnson and Johnson, Roche Holding AG, Pfizer Incorporated, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Incorporated, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Merck KGaA, Bio-Rad Laboratories Incorporated, Miltenyi Biotec B V and Co KG, Harbour BioMed Holding Limited, Zymeworks Inc., Adimab LLC, GeneTex Incorporated, Santa Cruz Biotechnology Incorporated, FabGennix Incorporated, EXBIO Praha spol s r o.

North America was the largest region in the cluster of differentiation 3 (CD3) antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cluster of differentiation 3 (cd3) antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cluster of differentiation 3 (cd3) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the CD3 antibody market by increasing costs of imported bioreactors, purification systems, active pharmaceutical ingredients, and analytical instruments required for antibody development and manufacturing. Pharmaceutical companies and research institutes in North America and Europe are most affected due to cross-border sourcing of biologics infrastructure, while Asia-Pacific faces cost pressure on antibody export manufacturing. These tariffs are raising development expenses and extending clinical timelines. At the same time, they are promoting domestic biologics manufacturing, regional supply chain localization, and investment in in-house antibody production capabilities.

The cluster of differentiation 3 (cd3) antibody market research report is one of a series of new reports that provides cluster of differentiation 3 (cd3) antibody market statistics, including cluster of differentiation 3 (cd3) antibody industry global market size, regional shares, competitors with a cluster of differentiation 3 (cd3) antibody market share, detailed cluster of differentiation 3 (cd3) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cluster of differentiation 3 (cd3) antibody industry. This cluster of differentiation 3 (cd3) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cluster of differentiation 3 (CD3) antibody is a monoclonal antibody that specifically binds to the CD3 complex on the surface of T lymphocytes. It is primarily used to modulate T-cell activity, making it valuable for immunotherapy and research applications. Depending on the therapeutic objective, it can promote T-cell activation, depletion, or redirection.

The main product types of CD3 antibodies include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, fragment crystallizable (Fc) engineering products, and others. Monoclonal antibodies are laboratory-engineered molecules designed to recognize and bind a single antigen, allowing precise targeting for diagnosis or therapy. The antibodies vary in molecular weight - low, medium, and high - and are available in aqueous and non-aqueous formulations. Key applications include cancer immunotherapy, autoimmune disease management, transplant rejection prevention, infectious disease treatment, and more. Primary end users comprise hospitals, research institutes, pharmaceutical companies, contract research organizations (CROs), and other healthcare and biotech entities.

The cluster of differentiation 3 (CD3) antibody market consists of sales of CD3 detection kits, flow cytometry reagents, fluorescent-labeled CD3 antibodies, immunohistochemistry reagents, western blot reagents, and CD3 diagnostic test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.